Scientific Advisory Group for Emergencies

Pathway to Cures Names First Members to Scientific Advisory Group

Retrieved on: 
星期二, 七月 18, 2023
Philanthropy, Health, Genetics, Fund Raising, Foundation, Pharmaceutical, Biotechnology, National Hemophilia Foundation, Bleeding, NHF, Gene editing, United States Air Force Scientific Advisory Board, Scientific Advisory Group, MBA, Scientific Advisory Group for Emergencies, Doctor of Philosophy, Science, Anemia, Blood, Sickle cell disease, Coagulopathy, Knowledge, Haemophilia, Pharmaceutical industry, MD, Pathway

Pathway to Cures (P2C), a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community, has named Katherine High, MD; Haiyan Jiang, PhD; Glenn Pierce, MD, PhD and Steven Pipe, MD, to its Scientific Advisory Group.

Key Points: 
  • Pathway to Cures (P2C), a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community, has named Katherine High, MD; Haiyan Jiang, PhD; Glenn Pierce, MD, PhD and Steven Pipe, MD, to its Scientific Advisory Group.
  • Leonard Valentino, MD, P2C’s Chief Executive Officer and NHF President and CEO, also serves on the Scientific Advisory Group.
  • Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Hemophilia Foundation (NHF) and chairs the Pathway to Cures Scientific Advisory Group.
  • P2C’s Scientific Advisory Board makes recommendations to the P2C Investment Committee regarding promising opportunities.

Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics

Retrieved on: 
星期五, 三月 24, 2023
Yale University, Mitochondrion, PTC Therapeutics, Drug development, University, Gene, The Conference Board, Conference call, PTC, Cancer, Eladocagene exuparvovec, Coronavirus Scientific Advisory Board, European Research Advisory Board, Brain, CMO, RNA, History, CNS, DSM-IV codes, EMA, Bachelor of Arts in Clinical Psychology, Biosensors and Bioelectronics, Shriners Hospitals for Children, ET, Retirement, Oxidative stress, Consultant, Patient, University of Washington Department of Global Health, Stuart, Growth, Mitochondrial disease, Rare, Therapy, Scientific Advisory Group for Emergencies, Conference, Stu, Management, Pharmaceutical industry, Vaccine, Nursing

SOUTH PLAINFIELD, N.J., March 24, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT). Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years. Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development. Under his leadership, PTC has grown from a research organization with expertise in the control of RNA processes to a publicly traded, integrated, global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of neurological and neuromuscular disorders, metabolic disorders, and cancer.

Key Points: 
  • Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years.
  • Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development.
  • What Stuart and the team have achieved in 25 years is extraordinary," said Michael Schmertzler, Chairman of the Board of Directors.
  • Matthew Klein, M.D., M.S., F.A.C.S., current Chief Operating Officer, has been named the company's CEO and will join the Board of Directors.

MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director

Retrieved on: 
星期二, 三月 7, 2023
Maker, GSK plc, Muscular dystrophy, University of Manchester, Therapy, Immunology, Pleasure, Royal Society, SAB, NewCo, Novartis, Neurology, Coronavirus Scientific Advisory Board, Manchester University NHS Foundation Trust, Neuromuscular disease, CDO, Glycogen storage disease, Journal of Specialised Translation, New Year Honours, Genetic distance, Consultant, Innovation, FRS, University, Nuffield Department of Population Health, Professor, Translational medicine, Royal, Keble College, Oxford, Anatomy, Government, Duchenne muscular dystrophy, AstraZeneca, Research, Scientific Advisory Group for Emergencies, NHS foundation trust, Biotechnology, Pharmaceutical industry, Management, Biology, Duchenne, Neuroscience, Child, Evotec

OXFORD, England, March 07, 2023 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing revolutionary therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces Christine Charman as Chief Development Officer, David Richardson as Finance Director, and four appointments to its Scientific Advisory Board (SAB): Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd C Schwahn.

Key Points: 
  • OXFORD, England, March 07, 2023 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing revolutionary therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces Christine Charman as Chief Development Officer, David Richardson as Finance Director, and four appointments to its Scientific Advisory Board (SAB): Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd C Schwahn.
  • He commented on his appointment: “It’s an honour and a pleasure to come together with top international scientific and clinical experts to build the MitoRx Scientific Advisory Board.
  • David Richardson BSc ACMA AMCT brings over 30 years finance experience to his new role as Finance Director.
  • Jonathan Rees PhD, CEO of MitoRx, said, “We are thrilled to welcome our new SAB members, as well as Christine Charman as Chief Development Officer and David Richardson as Finance Director, who together bring a wealth of renowned experience across financial, scientific and clinical backgrounds.

Theralink's Exclusive Licensed RPPA Technology for Commercial Laboratory Testing to Assist the White House Cancer Moonshot Initiative

Retrieved on: 
星期二, 一月 17, 2023
Scientific Advisory Group for Emergencies, University of Utah College of Science, Cancer, OTC, Molecular medicine, Government, Friends, Professor, George Mason University, College, Biology, Patient, Disease, Mortality, Research, DRS, Oncology, Breast cancer, Proteomics, Mason, Pharmaceutical industry, Science

"I think it's very realistic to reduce cancer death rates in half in 25 years," said Emanuel "Chip" Petricoin, a University Professor and the co-founder and co-director of CAPMM. Petricoin is also the Chair of Theralink's Scientific Advisory Board--where the mission is to bring this novel, highly sensitive, molecular profiling technology to cancer patients across the U.S. and to assist treating oncologists with therapy selection based upon each individual patient's biology.

Key Points: 
  • Mick Ruxin, M.D., Chief Executive Officer of Theralink said, "We are extremely excited to learn that the Reverse Phase Protein Assay (RPPA) technology will play a role in the Cancer Moonshot Initiative."
  • Previously, Theralink acquired an exclusive commercial license for the RPPA technology through an agreement with George Mason University.
  • Recently, George Mason University announced that Mason scientists would play a role in the White House Cancer Moonshot Initiative, and their work could help in the mission to reduce cancer rates.
  • The U.S. government is partnering with researchers to reduce cancer deaths by bringing together a large community of patients, advocates, researchers, and clinicians.

Global Thought Leaders Continue to Join the VESTECK Advisory Team

Retrieved on: 
星期四, 一月 5, 2023
Dai, University of Twente, Innovation, Aorta, EVAR, SAB, Elective surgery, Interventional radiology, Faculty, Scientific Advisory Group for Emergencies, Coronavirus Scientific Advisory Board (Turkey), University, Johannes Hoffmann (vascular surgeon), Management, Pharmaceutical industry

WEST CHESTER, Pa., Jan. 5, 2023 /PRNewswire/ -- VESTECK, Inc. is proud to announce that another global Endovascular thought leader, Professor Michel Reijnen has agreed to join the VESTECK Scientific Advisory Board.

Key Points: 
  • WEST CHESTER, Pa., Jan. 5, 2023 /PRNewswire/ -- VESTECK, Inc. is proud to announce that another global Endovascular thought leader, Professor Michel Reijnen has agreed to join the VESTECK Scientific Advisory Board.
  • The VESTECK "SUTURE-TIGHT"™ catheter secures endovascular aortic repair grafts (EVAR) to the aorta at the time of initial implant or during repair procedures.
  • VESTECK CEO, Joe Rafferty commented, "we are honored to have Professor Reijnen join our Scientific Advisory Board.
  • On the VESTECK Scientific Advisory Board, Professor Reijnen joins global thought leaders: Sean Lyden MD Cleveland Clinic, Daniel Clair MD Vanderbilt Univ., Prof. Andrew Holden Auckland Hosp NZ, William Gray MD Main Line Health, Dai Yamanouchi MD Univ.

BioNTech Establishes Asia-Pacific Clinical Scale mRNA Manufacturing & Regional Research Centre

Retrieved on: 
星期五, 十月 7, 2022
Scientific Advisory Group, Drug design, Infection, Fiji coup, RNA transfection, 1992 Victorian state election, Pandemic, Gaps, Vaccine, Laboratory, Pfizer, Scientific Advisory Group for Emergencies, Medical research, Patient, Biotechnology, RNA, Research, Entrepreneurship, Science, Investment, Partnership, Pfizer–BioNTech COVID-19 vaccine, BioNTech, CEO, GameChanger, Innovation, GLOBE, Clinical trial, Government, COVID-19, Pharmaceutical industry, Medical device, Aquaculture

In establishing its first Asia-Pacific clinical development and research collaboration centre in Melbourne, BioNTech will provide state-of-the-art drug development and translational research capabilities to the local ecosystem.

Key Points: 
  • In establishing its first Asia-Pacific clinical development and research collaboration centre in Melbourne, BioNTech will provide state-of-the-art drug development and translational research capabilities to the local ecosystem.
  • Founded in 2008 in Germany, BioNTech has become a world leader in mRNA research, especially in infectious disease and oncology.
  • "It is a coup for a global innovation leader like BioNTech to establish their regional research and clinical operations in Victoria.
  • BioNTech will accelerate the capability of the research community to translate their critical R&D into clinical outcomes at pace and scale."

Carolyn Bertozzi, Professor and Director of the Sarafan ChEM-H institute at Stanford University, Joins the Rondo Therapeutics Scientific Advisory Board

Retrieved on: 
星期三, 九月 7, 2022
Centre for Protein Engineering, AAAS, German Academy of Sciences at Berlin, University, Research, Tumor microenvironment, American Academy, Therapy, SAN, German National Academy of Sciences Leopoldina, Welch Award in Chemistry, Dickson Prize, Biochemistry, National, Glycosylation, Scientific Advisory Group for Emergencies, American Cancer Society, University of Pittsburgh, National academy, Biology, Immunotherapy, Wolf Prize, Immune system, United States Air Force Scientific Advisory Board, Stanford University, Sarafan, Patient, CMO, Pharmaceutical industry, Medicine, Rondo, Chemistry, Science, Biophysics

SAN FRANCISCO BAY AREA, Calif., Sept. 7, 2022 /PRNewswire/ -- Rondo Therapeutics, a privately-held biotechnology company advancing next-generation immuno-oncology platforms, announces the addition of Carolyn Bertozzi, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • SAN FRANCISCO BAY AREA, Calif., Sept. 7, 2022 /PRNewswire/ -- Rondo Therapeutics, a privately-held biotechnology company advancing next-generation immuno-oncology platforms, announces the addition of Carolyn Bertozzi, Ph.D., to its Scientific Advisory Board.
  • Dr. Bertozzi is a Professor of Chemistry and Director of the Sarafan ChEM-H institute at Stanford Universityand is a world leader in the field of glycobiology, generating new insights regarding disease-associated changes in cell surface glycosylation patterns.
  • Jessica Stark, Ph.D., an American Cancer Society postdoctoral fellow in the Bertozzi Research Group, is also joining Rondo as a scientific consultant.
  • Dr. Stark has pioneered new approaches in understanding the role of glycobiology in the functioning of the innate immune system.

Epic Bio, Founded by CRISPR Pioneer, Launches to Revolutionize Genetic Medicine With Epigenetic Engineering

Retrieved on: 
星期二, 七月 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Engineering, Manufacturing, Clinical Trials, Stanford University, AAV, GEMS, Gene expression, Gene, Biotechnology, Horizons Ventures, University of Maryland School of Medicine, Genetic engineering, Systems biology, University of Oxford, CRISPR interference, Coronavirus Scientific Advisory Board (Turkey), LinkedIn, Neuroscience, Genomics, University of California, Berkeley, CRISPR, Cas, Scientific Advisory Group for Emergencies, Bio, Patient, University of California, San Francisco, University of Washington Department of Bioengineering, Ludwig Cancer Research, Patent, Institute, Science Publishing Group, CRISPR/Cpf1, Human Genome Sciences, A1AD, Doctor of Philosophy, Department, Synthetic biology, Epigenome, Twitter, University, James D. Watson Institute of Genome Sciences, Industry, Maryland School, FSHD, Pharmaceutical industry, Vaccine, Management, Cas9, Biological engineering

Epic was founded by Stanley Qi, Ph.D., a renowned bioengineer and named co-inventor on the CRISPR patent held by the University of California.

Key Points: 
  • Epic was founded by Stanley Qi, Ph.D., a renowned bioengineer and named co-inventor on the CRISPR patent held by the University of California.
  • The company additionally launches with an exclusive license from Stanford University to the ultracompact DNA-binding protein CasMINI for human use.
  • The platform that Epic Bio has built is unparalleled in the field of epigenetic engineering.
  • Epic Bio was founded by Stanley Qi, Ph.D., whose fundamental work in epigenetic engineering includes the invention of CRISPRa (activation) and CRISPRi (interference).

DEM BioPharma Launches with $70 Million Financing

Retrieved on: 
星期四, 六月 23, 2022
Biotechnology, Pharmaceutical, Health, Oncology, CSO, Investment, Antibody, Phagocyte, Cancer, APMAP, DEM, Insight Partners, Scientific Advisory Group for Emergencies, Partner (business rank), Trillium, Genomics, HHMI, Whitehead Institute, National Academy of Sciences, Alta Partners, Â, CEO, EM, MIT, Coronavirus Scientific Advisory Board (Turkey), Chomp, CRISPR, Stanford University School of Medicine, Research, Science, Emerson Collective, Chemical substance, Dana–Farber Cancer Institute, Immunotherapy, Pfizer, Professor, Stanford University, DRS, Biomedical Research, Macrophage, Chemical engineering, Therapy, National academy, Phagocytosis, Neoplasm, Pharmaceutical industry, Vaccine, Interior design, Management, Genetics

DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune system checkpoints to eliminate cancer, today announced its initial $70 million financing led by founding investor Longwood Fund and Alta Partners , with additional participation from Insight Partners , Pfizer Ventures , Astellas Venture Management , Emerson Collective , UTokyo Innovation Platform and Alexandria Venture Investments .

Key Points: 
  • DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune system checkpoints to eliminate cancer, today announced its initial $70 million financing led by founding investor Longwood Fund and Alta Partners , with additional participation from Insight Partners , Pfizer Ventures , Astellas Venture Management , Emerson Collective , UTokyo Innovation Platform and Alexandria Venture Investments .
  • DEM Bio also announced the appointment of Jan Skvarka, former CEO of Trillium Therapeutics (acquired by Pfizer for $2.22 billion in November 2021), as Executive Chairman.
  • DEM Bios founders discovered a scalable approach to systematically unlock the potential of innate immune system checkpoints, noted Dr. Westphal.
  • The CHoMP platform has identified a number of promising new DEM/EM signals, including the novel DEM pathway APMAP.

Vasayo Welcomes New Chief Scientific Officer, Dr. Dan Gubler

Retrieved on: 
星期二, 六月 21, 2022
California Institute of Technology, Scientific Advisory Group for Emergencies, Biochemistry, Science, World, CEO, Colorado State University, International Forum on Energy Security for the Future, LLC, Leadership, Plant, Brigham Young University, Health, Nutrient, Chicago Innovation Awards, Brand Partners, Partnership, DSA, Beauty, Brigham Young, Doctor of Philosophy, Facebook, Life, Multimedia, Instagram, Management, Pharmaceutical industry

PLEASANT GROVE, Utah, June 21, 2022 /PRNewswire/ -- Vasayo, LLC (Vasayo.com), a leading provider of nutritional and personal care products powered by Advanced Delivery Technology, has announced the appointment of Dr. Dan Gubler, Ph.D., as Vasayo's Chief Scientific Officer and head of the Vasayo Scientific Advisory Board.

Key Points: 
  • PLEASANT GROVE, Utah, June 21, 2022 /PRNewswire/ -- Vasayo, LLC (Vasayo.com), a leading provider of nutritional and personal care products powered by Advanced Delivery Technology, has announced the appointment of Dr. Dan Gubler, Ph.D., as Vasayo's Chief Scientific Officer and head of the Vasayo Scientific Advisory Board.
  • "As a user of Vasayo products, I benefit every day from the power of its science-based formulations created with Advanced Delivery Technology," Gubler says.
  • "The vision and leadership of our founders, as well as the experience and credentials of Vasayo's Scientific Advisory Board are second-to-none.
  • "We are thrilled to welcome Dr. Gubler to Vasayo," says Daniel S. Picou, Vasayo Founder & CEO.